AKT1 and hepatocellular carcinoma: Using fibrin gel–based 3D-cultured HCC-TRCs, mechanistic studies demonstrated that alisertib suppresses xanthine and hypoxanthine production by inhibiting the AURKA–AKT signaling axis.